

# Pharmacy and Therapeutics Committee

## Agenda

**Thursday, March 21, 2019**  
**7:00 a.m. to 8:45 a.m.**  
**Cannon Health Building**  
**Room 125**

Persons who wish to address the P&T Committee may contact Bryan S. Larson at ([bslarson@utah.gov](mailto:bslarson@utah.gov)) prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.

- 1) Call to order ..... McKay Robinson, PharmD, Chair
  - a) Announce Quorum
- 2) Welcome and Introductions ..... McKay Robinson, PharmD, Chair
  - a) Review and Approval of Minutes
  - b) Housekeeping
    - i) Annual Training ..... Tony Patterson, Assistant Attorney General
- 3) DUR Board Update ..... Robyn Seely, PharmD
- 4) Review
  - a) Insulins - Rapid Acting ..... Valerie Martinez, PharmD
    - i) insulin aspart, insulin glulisine, insulin lispro, insulin regular
  - b) Insulins - Basal ..... Valerie Gonzales, PharmD
    - i) insulin degludec, insulin detemir, insulin glargine
  - c) ACE Inhibitors/ACE Inhibitor Combinations ..... TBD
    - i) benazepril, benazepril/hctz, captopril, captopril/hctz, enalapril, enalapril/hctz, fosinopril, Fosinopril/hctz, lisinopril, lisinopril/hctz, moexipril, moexipril/hctz, perindopril, quinapril, quinapril/hctz, ramipril, trandolapril
  - d) Public Comment
  - e) Other States Report ..... Bryan S. Larson, PharmD
  - f) Committee Discussion/Questions
  - g) Committee Action
- 5) Next Meeting TBD Topic: TBD
- 6) Adjourned ..... McKay Robinson, PharmD, Chair

The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to:

Dr. Joanne LaFleur  
College of Pharmacy  
30 South 2000 East  
SLC, UT 84112-5820

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

#### **Tentative Upcoming Pharmacy & Therapeutics Committee Schedule**

Month	Topic	Agents
20 Jun 2019	ADHD Stimulants	<i>amphetamine, dextmethylphenidate, dextroamphetamine, dextroamphetamine/amphetamine mixed salts, lisdexamfetamine, methamphetamine, methylphenidate</i>
20 Jun 2019	Atypical Antipsychotics	<i>aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone</i>
20 Jun 2019	Sedative Hypnotics	<i>doxepin, eszopiclone, ramelteon, suvorexant, tasimelteon, zaleplon, zolpidem</i>
19 Sep 2019	TBD	<i>TBD</i>

**Please note: all topics are tentative and subject to change.**